196487
4-Biphenylacetic acid
98%
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
C6H5C6H4CH2CO2H
CAS Number:
Molecular Weight:
212.24
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
EC Number:
227-233-2
MDL number:
Assay:
98%
General description
4-Biphenylacetic acid is a potential non-steroidal antiinflammatory agent and forms solid inclusion complex with β-cyclodextrin. 4-Biphenylacetic acid on interaction with quinolone antibacterial agents induces functional blockade of the γ-aminobutyric acid receptors.
Application
4-Biphenylacetic acid was used in the synthesis of gastrosparing non-steroidal antiinflammatory drug.
signalword
Danger
Hazard Classifications
Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
K Akahane et al.
Antimicrobial agents and chemotherapy, 38(10), 2323-2329 (1994-10-01)
The combination of some new quinolone antibacterial agents with 4-biphenylacetic acid (BPAA), a metabolite of fenbufen, is known to specifically induce functional blockade of the gamma-aminobutyric acid (GABA) receptors. The mechanisms of these drug interactions were further examined. Scatchard analysis
G Puglisi et al.
The Journal of pharmacy and pharmacology, 43(6), 430-432 (1991-06-01)
4-Biphenylacetic acid, a potent non-steroidal anti-inflammatory agent forms a solid inclusion complex with beta-cyclodextrin in a 1:1 molar ratio, which exhibits better solubility and dissolution characteristics than the uncomplexed drug. Following oral administration of the complex to rats, quicker and
N Yi Mok et al.
Journal of medicinal chemistry, 56(5), 1843-1852 (2013-02-05)
β-Secretase (BACE1), the enzyme responsible for the first and rate-limiting step in the production of amyloid-β peptides, is an attractive target for the treatment of Alzheimer's disease. In this study, we report the application of the de novo fragment-based molecular